For the quarter ended June 2026, Royalty Pharma (RPRX Quick QuoteRPRX - Free Report) reported revenue of $773 million, up 6.3% over the same period last year. EPS came in at $1.32, compared to $1.14 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $761.4 million, representing a surprise of +1.52%. The company delivered an EPS surprise of +3.94%, with the consensus EPS estimate being $1.27.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Royalty Pharma performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Portfolio Receipts- Royalty Receipts- Products- Cystic fibrosis franchise: $194 million versus $196.14 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a 0% change.
• Portfolio Receipts- Royalty Receipts- Products- Imdelltra: $17 million versus $18.06 million estimated by two analysts on average.
• Portfolio Receipts- Royalty Receipts- Products- Imbruvica: $36 million versus $34.81 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -18.2% change.
• Portfolio Receipts- Royalty Receipts- Products- Xtandi: $44 million versus $43.92 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +4.8% change.
• Portfolio Receipts- Royalty Receipts- Products- Promacta: $8 million versus $6.54 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -75.8% change.
• Portfolio Receipts- Royalty Receipts- Products- Tremfya: $57 million compared to the $63.28 million average estimate based on two analysts. The reported number represents a change of +54.1% year over year.
• Portfolio Receipts- Royalty Receipts- Products- Cabometyx/Cometriq: $23 million compared to the $22.24 million average estimate based on two analysts. The reported number represents a change of +15% year over year.
• Portfolio Receipts- Royalty Receipts- Products- Evrysdi: $47 million versus the two-analyst average estimate of $48.36 million. The reported number represents a year-over-year change of +42.4%.
• Portfolio Receipts- Royalty Receipts- Products- Trodelvy: $14 million versus $12.09 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +40% change.
• Portfolio Receipts- Royalty Receipts- Products- Other products: $139 million versus $116.3 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +41.8% change.
• Portfolio Receipts- Royalty Receipts- Products- Royalty Receipts: $768 million compared to the $753.9 million average estimate based on two analysts. The reported number represents a change of +14.3% year over year.
• Portfolio Receipts- Royalty Receipts- Products- Trelegy: $58 million versus the two-analyst average estimate of $57.65 million. The reported number represents a year-over-year change of +1.8%.

View all Key Company Metrics for Royalty Pharma here>>>

Shares of Royalty Pharma have returned -0.6% over the past month versus the Zacks S&P 500 composite's +3.5% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.